16 December 2017 - The aim of this study was to examine submissions made to the PBAC and assess whether the predicted financial impact was associated with a recommendation. 

The second objective was to assess whether the financial and utilisation estimates for listing the proposed medicine were reliable.

In 2012 to 2014, the PBAC considered 142 unique major submissions; of those, 65 were recommended for listing. A higher financial cost to the government was a statistically significant factor in predicting rejection (p = .004 for cost > AUD 30 million Australian dollars [20.7 million Euros] compared with cost-saving).

Read International Journal of Technology Assessment in Health Care article